文献速递白血病

儿童标准危B淋巴母细胞白血病减少长春新碱和地塞米松脉冲频率的优异结局:COG AALL0932研究结果

Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.
PubMed 文献 · J Clin Oncol · 2021-01-07

AALL0932研究纳入9229例新诊断B-ALL患儿,其中2364例平均危患者维持治疗期随机接受每4周或每12周长春新碱/地塞米松脉冲,以及每周口服甲氨蝶呤20或40 mg/m2起始剂量。结果显示每12周脉冲组5年DFS和OS与每4周组无显著差异,且甲氨蝶呤40 mg/m2未优于20 mg/m2,减少脉冲频率已纳入COG前线试验。

要点

  • 平均危B-ALL维持期每12周长春新碱/地塞米松脉冲的5年DFS和OS与每4周无显著差异。
  • 每周甲氨蝶呤起始剂量40 mg/m2与20 mg/m2相比未改善结局。
  • 减少长春新碱/地塞米松脉冲频率已纳入COG前线B-ALL试验以减轻治疗负担。

核心结论

  • NCI标准危平均危B-ALL患者接受每12周长春新碱/地塞米松脉冲的结局优异,尽管脉冲数为既往COG试验标准的三分之一。
  • 甲氨蝶呤每周起始剂量40 mg/m2与20 mg/m2相比未改善结局。
  • 减少长春新碱/地塞米松脉冲频率已纳入COG前线B-ALL试验。

研究设计与样本

  • AALL0932研究纳入9229例B-ALL患者,其中2364例平均危患者在维持治疗开始时按2×2析因设计随机。
  • 随机干预为长春新碱/地塞米松脉冲每4周或每12周,以及每周口服甲氨蝶呤起始剂量20 mg/m2或40 mg/m2。

主要发现

  • 所有 eligible 且可评估的SR B-ALL患者(n=9226)自入组起5年EFS为92.0%(95%CI 91.1%–92.8%),OS为96.8%(95%CI 96.2%–97.3%)。
  • 随机分配的平均危患者自维持治疗起5年DFS为94.6%(95%CI 93.3%–95.9%),OS为98.5%(95%CI 97.7%–99.2%)。

临床怎么用

  • 对于NCI标准危平均危B-ALL患儿,维持治疗期可采用每12周长春新碱/地塞米松脉冲以减轻治疗负担。
  • 每周口服甲氨蝶呤起始剂量20 mg/m2即可,无需提高至40 mg/m2。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia (B-ALL). METHODS: AALL0932 enrolled 9,229 patients with B-ALL; 2,364 average-risk (AR) patients were randomly assigned (2 × 2 factorial design) at the start of maintenance therapy to vincristine/dexamethasone pulses every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks, and a starting dose of weekly oral methotrexate of 20 mg/m2 (MTX20) or 40 mg/m2 (MTX40). RESULTS: Five-year event-free survival and overall survival (OS) from enrollment (with 95% CIs), for all eligible and evaluable SR B-ALL patients (n = 9,226), were 92.0% (91.1% and 92.8%) and 96.8% (96.2% and 97.3%), respectively. The 5-year DFS and OS from the start of maintenance for randomly assigned AR patients were 94.6% (93.3% and 95.9%) and 98.5% (97.7% and 99.2%), respectively. The 5-year DFS and OS for patients randomly assigned to receive VCR/DEX4 (n = 1,186) versus VCR/DEX12 (n = 1,178) were 94.1% (92.2% and 96.0%) and 98.3% (97.2% and 99.4%) v 95.1% (93.3% and 96.9%) and 98.6% (97.7% and 99.6%), respectively (P = .86 and .69). The 5-year DFS and OS for AR patients randomly assigned to receive MTX20 versus MTX40 were 95.1% (93.3% and 96.8%) and 98.8% (97.9% and 99.7%) v 94.2% (92.2% and 96.1%) and 98.1% (97.0% and 99.2%), respectively (P = .92 and .89). CONCLUSIONS: The 0NCI-SR AR B-ALL who received VCR/DEX12 had outstanding outcomes despite receiving one third of the vincristine/dexamethasone pulses previously used as standard of care on Children's Oncology Group (COG) trials. The higher starting dose of MTX of 40 mg/m2/week did not improve outcomes when compared with 20 mg/m2/week. The decreased frequency of vincristine/dexamethasone pulses has been incorporated into frontline COG B-ALL trials to decrease the burden of therapy for patients and their families.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Angiolillo AL, Schore RJ, Kairalla JA, et al. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021. PMID: 33411585. doi:10.1200/JCO.20.00494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。